Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP.
Rapport Therapeutics Inc. (RAPP)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cormorant Asset Management Bihua Chen | 2,957,521 | $92,540,832 | -3% | 4.65% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,642,461 | $51,392,605 | +64% | 0.18% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,547,090 | $48,408,446 | 0.28% | |
| 4. | Vestal Point Capital Ryan Wilder | 1,436,229 | $44,939,605 | +30% | 1.26% |
| 5. | Perceptive Advisors Joseph Edelman | 673,923 | $21,087,051 | 0.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.48 | 20,400 | $499,373.64 | 20,400 | 2025-09-12 | Filing | |
| $24.97 | 13,382 | $334,164.60 | 41,666 | 2025-09-12 | Filing | |
| $24.50 | 28,284 | $692,946.69 | 28,284 | 2025-09-12 | Filing | |
| $22.60 | 3,500 | $79,100.00 | 9,500 | 2025-09-11 | Filing | |
| $9.98 | 100 | $998.00 | 10,000 | 2025-03-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.05 | 18,572 | $743,752.88 | 6,280,525 | 2026-05-26 | Filing | |
| $40.24 | 133,618 | $5,377,322.79 | 6,299,097 | 2026-05-11 | Filing | |
| $40.31 | 5,018 | $202,255.51 | 6,432,715 | 2026-05-08 | Filing | |
| $40.12 | 271,495 | $10,892,650.90 | 6,437,733 | 2026-05-07 | Filing | |
| $40.32 | 426,005 | $17,175,243.59 | 6,709,228 | 2026-04-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,168,939 | $224,316,101 | 0.01% | |
| 2. | 7,135,233 | $223,261,441 | 55.68% | |
| 3. | 3,728,738 | $116,672,212 | 17.23% | |
| 4. | 3,097,973 | $96,935,575 | 0.02% | |
| 5. | 2,942,251 | $92,063,034 | 0.01% |
News See All
10 Stocks That Have the Potential to Rise 1000%
Stocks with high upside are rarely obvious at the start. The market usually sees a small company, an unproven business model, or a story that still needs execution.
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc.
11 Best Fast Money Stocks to Buy Now
In this fast-paced world, most people have become impatient. Everyone is drawn to whatever delivers quick results, whether it be fast fame or fast money.
Hedge Fund Resource Center